Menlo Park, CA, United States of America

Jens-Peter Volkmer

USPTO Granted Patents = 30 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 12)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 124(Granted Patents)

Company Filing History:

26 out of 5,303

Leland Stanford Junior University

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

30 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12318448 - Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells (2025-06-03),

2. 12274746 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2025-04-14),

3. 12258403 - Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody (2025-03-25),

4. 12258399 - Methods for achieving therapeutically effective doses of anti-CD47 agents (2025-03-25),

5. 12194093 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2025-01-14),

6. 12037402 - Treatment of cancer with dual targeting of CD47 and EGFR (2024-07-16),

7. 11891450 - Anti-CD47 agent-based treatment of CD20-positive cancer (2024-02-06),

8. 11802153 - Anti-CD47 agent-based ovarian cancer therapy (2023-10-31),

9. 11766454 - Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells (2023-09-26),

10. 11753480 - Anti-SIRP-alpha antibodies and related methods (2023-09-12),

11. 11718675 - Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy (2023-08-08),

12. 11718670 - Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer (2023-08-08),

13. 11603404 - Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody (2023-03-14),

14. 11518806 - Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody (2022-12-06),

15. 11472878 - Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer (2022-10-18),

Title: The Innovative Journey of Jens-Peter Volkmer

Introduction: Jens-Peter Volkmer is a visionary inventor based in Menlo Park, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Jens-Peter Volkmer holds several patents in the areas of artificial intelligence, machine learning, and renewable energy technologies, showcasing his commitment to pushing the boundaries of what is possible in the modern world.

Career Highlights: With a career spanning over two decades, Jens-Peter Volkmer has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries. His innovative spirit and dedication to excellence have earned him recognition as a pioneer in his field.

Collaborations: Jens-Peter Volkmer has collaborated with top engineers, scientists, and researchers from around the globe, fostering a culture of creativity and innovation that has led to the development of groundbreaking technologies with real-world applications.

Conclusion: Jens-Peter Volkmer's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs. His impact on the world of technology is truly remarkable, and his legacy will undoubtedly shape the future of innovation for years to come.

This text is generated by artificial intelligence and may not be accurate.